Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) generates frequent news flow as a clinical-stage company developing natural and engineered bacteriophage therapies targeting specific pathogenic bacteria. Company press releases and Form 8-K filings describe how BiomX advances phage cocktails and personalized phage treatments for chronic conditions, including cystic fibrosis-related lung infections and diabetic foot disease. News coverage often centers on clinical trial progress, regulatory feedback, financing transactions and strategic updates that can influence the outlook for PHGE stock.
A major theme in BiomX news is the development of its phage product candidates. For BX004, a fixed multi-phage cocktail for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, the company has reported Phase 1b/2a data, FDA Fast Track and Orphan Drug designations, initiation of a Phase 2b trial, an FDA clinical hold related to a third-party nebulizer device, and ultimately the discontinuation of the Phase 2b study after internal review and Data Monitoring Committee feedback. Separate updates detail European enrollment, FDA correspondence on potential Phase 3 pathways, and safety reviews.
News items also highlight BiomX’s diabetic foot programs. The company has announced statistically significant positive topline Phase 2 results for BX211 in diabetic foot osteomyelitis and subsequent FDA feedback supporting the development pathway for BX011, a next-generation fixed multi-phage cocktail targeting Staphylococcus aureus in diabetic foot infections. Releases describe the rationale for prioritizing DFI, the incorporation of proprietary phages, and the role of non-dilutive funding from U.S. Defense Health Agency and Department of Navy-related sources.
Investors following PHGE can also expect updates on corporate and financial events, such as reverse stock split decisions, private placements of Series Y Convertible Preferred Stock and warrants, lease terminations at subsidiaries, and cost-cutting measures including workforce reductions. Together, these disclosures provide a detailed, evolving picture of BiomX’s clinical pipeline, regulatory interactions, capital structure and strategic alternatives. Bookmark this page to review new PHGE press releases, trial milestones and SEC-reported events as they are published.
BiomX (NYSE: PHGE) announced its Q4 and full year 2024 financial results, highlighting key developments in its phage therapy programs. The company secured $12 million in financing in February 2025 to support its Phase 2b study of BX004. Key financial metrics include:
- Cash balance of $18.0 million as of December 31, 2024
- R&D expenses increased to $24.7 million in 2024
- Net loss decreased to $17.7 million in 2024
- Operating cash burn of $37 million in 2024
Clinical Updates:
- BX211 Phase 2 topline results for diabetic foot osteomyelitis expected by end of March 2025
- BX004 Phase 2b topline results for cystic fibrosis anticipated in Q1 2026
- Received $36.8 million in non-dilutive funding from DHA for BX211 trial
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria, has announced it will release its fourth quarter and full year 2024 financial results on March 25, 2025.
The financial results will be accessible through a press release in the Investors section of BiomX's website. The company plans to host a conference call and audio webcast at a later date, which will coincide with the announcement of initial topline results from its Phase 2 trial investigating treatments for subjects with diabetic foot osteomyelitis.
BiomX Inc. (NYSE American: PHGE) has secured $12 million in financing through a series of offerings, including a registered direct offering and concurrent private placement. The funding will support the advancement of their BX004 program through Phase 2b study in cystic fibrosis patients, with topline results expected in Q1 2026.
The offerings were led by Deerfield Management Company with significant participation from the Cystic Fibrosis Foundation and Nantahala Capital. The financing includes the purchase of 3,633,514 shares of common stock at $0.9306 per share, along with warrants for additional shares. The company will also analyze real-world evidence exploring the relationship between P. aeruginosa reduction and clinical outcomes in CF patients.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focusing on phage therapies targeting specific pathogenic bacteria, announced that it has received a written notification from NYSE American , dated December 10, 2024. The notification confirms that BiomX has regained compliance with all NYSE American continued listing standards. This compliance rectifies the deficiencies noted on May 23, 2024, as outlined in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. NYSE American verified that BiomX has met the continued listing standards for two consecutive quarters, in accordance with Section 1009(f) of the Company Guide.
BiomX announced Q3 2024 financial results and clinical program updates. Patient enrollment for BX211 Phase 2 trial in Diabetic Foot Osteomyelitis is complete, with topline results expected in Q1 2025. The BX004 Phase 2b study in Cystic Fibrosis faced manufacturing delays, now resolved, with results expected in H1 2026. Cash balance was $24.7M as of September 30, 2024. R&D expenses increased to $7.3M from $5.6M year-over-year. The company reported net income of $9.6M compared to a net loss of $7.9M in Q3 2023, mainly due to changes in warrant fair value. Cash runway extends into Q4 2025.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on natural and engineered phage therapies, has scheduled a conference call and webcast for November 14, 2024, at 8:00 a.m. ET. The event will cover the company's third quarter 2024 financial results, business updates, and program developments. Participants can join via phone at 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The webcast will be accessible through the Investors section of BiomX's website.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing phage therapies targeting specific pathogenic bacteria, has announced a mandatory separation of its units (PHGE.U). Each unit consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock. The separation will occur on or about October 25, 2024, after which the units will no longer trade on the NYSE American.
Key points:
- Unit holders will receive the underlying shares of Common Stock and Warrants
- The separation is automatic, requiring no action from unit holders
- Warrants will expire on October 28, 2024
- Each warrant allows purchase of one-half share at $115 per share
- Post-separation, Common Stock will trade under the symbol PHGE
BiomX Inc. (NYSE American: PHGE) will present updated data from its Phase 1b/2a study of BX004 for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at the North American Cystic Fibrosis Conference in Boston. The findings will be showcased in a poster session on September 27, 2024, and discussed in a workshop on September 28, 2024.
Key results include:
- Greater reduction in P. aeruginosa colony-forming units in subjects receiving BX004-A compared to placebo
- 14% of BX004-A recipients had negative P. aeruginosa sputum culture at treatment end, versus 0% for placebo
- Improved lung function (FEV1) in a subgroup of BX004-A recipients (+5.66%) compared to placebo (-3.23%)
The study's six-month follow-up has been completed for all subjects.
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel phage therapies targeting specific pathogenic bacteria, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel.
Key details include:
- CEO Jonathan Solomon will present a corporate overview
- Presentation Date: September 9, 2024
- Time: Available on-demand from 7:00 AM ET
- Webcast link provided for virtual attendance
- Replay available on BiomX's website for 90 days
Mr. Solomon will also be available for one-on-one meetings during the conference. Interested parties can register and request meetings through the provided link.
BiomX Inc. (NYSE American: PHGE) will present positive Phase 1b/2a clinical trial data for BX004, a novel phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients, at the European Respiratory Society Congress 2024. The study demonstrated favorable safety and notable microbiologic and clinical efficacy, even in patients on standard care treatment. Key findings include:
1. Greater reduction in P. aeruginosa colony-forming units in treated subjects vs. placebo
2. 14% of treated subjects had negative P. aeruginosa sputum culture at treatment end
3. Improved lung function in a subgroup of treated patients
4. No treatment-related phage resistance or serious adverse events
BiomX CEO Jonathan Solomon expressed encouragement about the results, highlighting the potential of their novel approach in treating cystic fibrosis.